An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease

NCT02245737 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

2218

Enrollment

INDUSTRY

Sponsor class

Stopped An independent assessment concluded the trial was not likely to meet the primary endpoint upon completion and therefore, trial stopped for futility

Conditions

Alzheimer´s Disease

Interventions

DRUG: Lanabecestat
DRUG: Placebo

Sponsor

AstraZeneca

Collaborators

[object Object]